Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

266 results about "Opioidergic" patented technology

An opioidergic agent (or drug) is a chemical which functions to directly modulate the opioid neuropeptide systems (i.e., endorphin, enkephalin, dynorphin, nociceptin) in the body or brain. Examples include opioid analgesics such as morphine and opioid antagonists such as naloxone. Opioidergics also comprise allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.

Pharmaceutical composition for nasal delivery

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
Owner:OREXO AB

Method of making wet wipe for rapid detection of opioids

A substance detector includes curcumin and is safe for human handling. The curcumin, as part of a wetting agent of the substance detector, changes color on contact with opioids and related illicit substances. A corresponding method detects very small quantities of an opioid via a rapid color change on a wet wipe when contacted with the opioid. Because the color change takes place on the wet wipe relatively quickly, there is no need to mix reagents to produce a color change reaction.
Owner:THE UNIVERSITY OF AKRON

Gynecological postoperative rehabilitation path personalized planning and management system and method

The invention discloses a gynecological postoperative rehabilitation path personalized planning and management system and method. The method comprises the following steps: S1, collecting patient data; s2, according to the collected patient data, analyzing and predicting management plans of analgesic drugs of the patient in different rehabilitation paths, and selecting a preliminary rehabilitation path; s3, evaluating and continuously recording at different postoperative time points; and S4, simulating and predicting analgesic effects and possible adverse reactions in different rehabilitation paths at different time points, and correcting the preliminary rehabilitation path. By presetting a personalized analgesic scheme and continuously evaluating the pain state and the analgesic effect of the patient, the patient can obtain the optimal analgesic effect at different rehabilitation points in a short period after the operation, the use of opioid drugs is selectively reduced while effective analgesia is ensured, the occurrence rate of side effects of the opioid drugs is effectively reduced, and the pain relieving effect of the patient is improved. The dependence and addiction risk of patients on opioid drugs are also reduced, and the safety of the rehabilitation process is improved.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Kappa opioid receptor peptide amide ligands

The present invention provides kappa opioid receptor peptide agonists, methods for preparing these compounds, compositions comprising these kappa opioid receptor peptide agonists, and methods of using the kappa opioid receptor peptide agonists to treat pain or other conditions.
Owner:YICHANG HUMANWELL PHARMA CO LTD

Methods for acute and long-term treatment of opioid and opioid-like drug addiction

This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt or solvate thereof at a dosage that provides an average serum concentration of about 50 ng / mL to about 850 ng / mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
Owner:ATAI THERAPEUTICS INC

Wet wipe for rapid detection of opioids

PendingUS20250003886A1OpioidergicIllicit Substance
A substance detector includes curcumin and is safe for human handling. The curcumin, as part of a wetting agent of the substance detector, changes color on contact with opioids and related illicit substances. A corresponding method detects very small quantities of an opioid via a rapid color change on a wet wipe when contacted with the opioid. Because the color change takes place on the wet wipe relatively quickly, there is no need to mix reagents to produce a color change reaction.
Owner:THE UNIVERSITY OF AKRON

Wet wipe for rapid detection of opioids with alcohol as preservative

PendingUS20250003995A1Cosmetic preparationsToilet preparationsOpioidergicIllicit Substance
A substance detector includes curcumin and is safe for human handling. The curcumin, as part of a wetting agent of the substance detector, changes color on contact with opioids and related illicit substances. A corresponding method detects very small quantities of an opioid via a rapid color change on a wet wipe when contacted with the opioid. Because the color change takes place on the wet wipe relatively quickly, there is no need to mix reagents to produce a color change reaction.
Owner:THE UNIVERSITY OF AKRON

Nonmuscle myosin ii inhibitors

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Nicotine Delivery Systems

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).
Owner:BREATHEASY CO D B A MIIST THERAPEUTICS

Methods of treating respiratory depression modulated by a non-opioid agent

Disclosed in certain embodiments is a method of treating respiratory depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
Owner:ENALARE THERAPEUTICS INC

Aerosol delivery systems

PCT designated stage expiredWO2025006372A1Organic active ingredientsPowder deliveryOpioidergicInhalation
Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).
Owner:BREATHEASY CO D B A MIIST THERAPEUTICS

Methods and pharmaceutical compositions to treat drug overdose

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.
Owner:ENALARE THERAPEUTICS INC

Genetic Variants Associated with Opioid Use Disorder

Methods and kits for diagnosing a likelihood of developing opioid use disorder (OUD) using single nucleotide polymorphisms (SNPs) are described. Also described is a method of predicting a likelihood of a subject experiencing an opioid overdose.
Owner:OFFICE OF THE OHIO ATTORNEY GENERAL

Apparatus, methods, and systems for providing pharmaceutical compositions and administering medications to patients

A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery. This system offers precision and adaptability in treating conditions related to opioid overdose, dependency, and xylazine exposure.
Owner:MICRONEB TECH HLDG INC

Compositions and methods related to aptamer-based colorimetric assays

The present disclosure provides compositions and methods related to opioid detection. In particular, the present disclosure provides aptamer-based colorimetric assays for the visualization and identification of specific opioids (natural, semi-synthetic, synthetic and the derivatives and analogs thereof) in a manner that is rapid, specific, and sensitive.
Owner:NORTH CAROLINA STATE UNIV

Portable emergency response kits with integrated signal transmission system

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.
Owner:FFF ENTERPRISES

System and methods for determining propensity to opioid addiction

PCT designated stage expiredWO2025038665A1Organic active ingredientsNervous disorderOpioidergicAssay
Embodiments include methods of determining a patient's susceptibility (i.e., risk) of becoming dependent and / or addicted to an addictive substance. The addictive substance can be an opioid receptor agonist. In aspects, the methods include use of a lateral flow assay (LFA) test with up converting phosphors (UCPs). If a patient is deemed susceptible to addiction, a monitoring / dispensing system can be used to administer the addictive substance (e.g., opioid receptor agonist).
Owner:GATC HEALTH CORP

Humanized non-opioid composition and therapies for pain management

A humanized anti-human P2X4R antibody, or an antigen binding fragment thereof, or a polypeptide, that inhibits human P2X4R activity, is provided as well as methods of making and using the antibody or an antigen binding fragment thereof.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +2

Design, synthesis, and biological evaluation of nitrogen-walk derivatives of nan as MU opioid receptor selective modulators

PCT designated stage expiredWO2025038406A1Organic active ingredientsNervous disorderDiseaseOpioidergic
A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.
Owner:VIRGINIA COMMONWEALTH UNIV

Use of phenylquinolinone and flavonoid derivatives in the preparation of drugs for treating neuropathic pain

The present invention provides the use of phenylquinolinone and flavonoid derivatives for neuropathic pain, and the phenylquinolinone and flavonoid derivatives include pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, which has a different mechanism of action from existing drugs and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention in treating neuropathic pain is better than amitriptyline, gabapentin, pregabalin and carbamazepine, indicating that the compound of the present invention has a better therapeutic effect, has the characteristics of small dosage, good efficacy, high bioavailability and safety, and compared with opioid drugs, the compound of the present invention is not addictive and is a very effective drug for treating neuropathic pain diseases. Therefore, the clinical application prospects are huge. The general structural formula is as follows:
Owner:HANGZHOU BIO SINCERITY PHARMA TECH CO LTD

Preparation of abuse-deterrent pharmaceutical formulations using vapor phase deposition

The disclosure is directed at an abuse-deterrent pharmaceutical composition comprising a coated antagonist particle, and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. Methods for manufacturing such an abuse-deterrent pharmaceutical composition are also provided.
Owner:APPLIED MATERIALS INC

Methods and apparatuses for opioid overdose prevention

ActiveUS12718917B2OpioidergicOpioid overdose
Methods and apparatuses for opioid overdose prevention are described. The apparatus comprises a memory and at least one processor coupled to the memory. The processor is configured to receive one or more measurements related to one or more vitals of a user, and cause, based on the one or more measurements, administration of a first dose of an overdose prevention medication to the user.
Owner:JAIN UMANG +2

Small molecule antagonist to pacap receptor and uses thereof

The disclosure relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), panic disorder, anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).
Owner:UNIVERSITY OF VERMONT

Respiratory-cardiac arrest detection and drug overdose treatment system

PendingUS20250375157A1SensorsDiagnostic recording/measuringBenzodiazepineExpired drug
The invention system is a wearable device that detects an impending or onset of cardio-respiratory arrest and remediates the condition by injecting an appropriate reversal drug depending upon the drug that triggered the arrest. It can detect and remediate arrests caused by drugs such as opioids, benzodiazepine or alcohol. Using self-test and other checks, it ensures that the system is operationally ready and that no near-expiration or expired drug is administered.
Owner:SASSANO JOHN

Use of mas-related g protein coupled receptor d in the peripheral nervous system in alleviating opioid tolerance

The application discloses application of a peripheral nervous system Mas-related G protein-coupled receptor D as a target point in preparation of a medicine for screening for relieving opioid tolerance. Jun The application further provides a medicine composition for regulating opioid tolerance, containing a Mas-related G protein-coupled receptor D siRNA sequence shown in SEQ ID NO. 1 or a siRNA sequence shown in SEQ ID NO. 2. The application further provides an in-situ hybridization kit for detecting expression of a Mas-related G protein-coupled receptor D gene in a dorsal root ganglion tissue of a peripheral nervous system. The application expands a new path for opioid companion diagnosis and intervention.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Artificial Intelligence Hospital Decision Ventilation Settings

This invention discloses a real-time monitoring system that detects and mitigates opioid-induced respiratory depression in clinical settings. The system integrates hospital sensors (e.g., capnography, pulse oximetry) with opioid pharmacokinetic data to assess ventilation risk dynamically. In one embodiment, a predictive algorithm calculates a risk score based on respiratory deviations and drug concentration, triggering tiered alerts for early intervention. Alternatively, an automated mitigation protocol pauses opioid infusion, suggests corrective actions, and documents events in electronic health records. The invention improves patient safety by proactively identifying ventilation conflicts, reducing reliance on threshold-based alarms.
Owner:RUBY BRENDAN

Novel kappa opioid ligands

The invention provides novel ligands of Kappa (κ) opioid receptors, such as can be used to modulate a Kappa opioid receptor. Methods of synthesis and methods of use are also provided. Compounds of the invention can be used therapeutically in the treatment of dissociative disorders or pain, or to provide neuroprotection, or to induce diuresis, or to modulate the immune system, or for treatment of one or more of an affective disorders comprising depression or stress / anxiety; an addictive disorder; alcoholism, epilepsy; a cognition deficiency; schizophrenia; Alzheimer's disease; or pain.
Owner:THE SCRIPPS RES INST

Compositions for treating addiction, dependence, withdrawal, and / or opioid induced hyperalgesia

A compound having a structure of formula (I), (II), (III), (IV), (V), (VI), or a pharmaceutically acceptable salt, a tautomer, or a solvate thereof for use in treating opioid addiction, withdrawal and / or dependence and / or loss of opioid induced analgesia and / or occurrence of opioid induced hyperalgesia in a subject in need thereof.
Owner:CASE WESTERN RESERVE UNIV +1